Intracellular cotrafficking of factor VIII and von Willebrand factor type 2N variants to storage organelles

Blood

Volumn 113, Issue 13, 2009, Pages 3102-3109

  Van Biggelaar, Maartje Den ^a,b   Meijer, Alexander B ^a,b   Voorberg, Jan ^a,c   Mertens, Koen ^a,b  

^a SANQUIN RESEARCH   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; PADGEM PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR TYPE 2N;

ARTICLE; BINDING AFFINITY; CELL ORGANELLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN VARIANT; WEIBEL PALADE BODY;

EID: 63849281084     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-05-159699     Document Type: Article

References (52)

1. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6:217-246.
2. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood. 1998;92:3983-3996.
3. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4:2103-2114.
4. Verweij CL, Diergaarde PJ, Hart M, Pannekoek H. Full-length von Willebrand factor(vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J. 1986;5:1839-1847.
5. Voorberg J, Fontijn R, Calafat J, Janssen H, van Mourik JA, Pannekoek H. Assembly and routing of von Willebrand factor variants: the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids. J Cell Biol. 1991;113:195-205.
6. Carew JA, Browning PJ, Lynch DC. Sulfation of von Willebrand factor. Blood. 1990;76:2530-2539.
7. Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood. 1994;83:3536-3544.
8. Wagner DD, Saffaripour S, Bonfanti R, et al. Induction of specific storage organelles by von Willebrand factor propolypeptide. Cell. 1991;64:403-413.
9. Voorberg J, Fontijn R, Calafat J, Janssen H, van Mourik JA, Pannekoek H. Biogenesis of von Wil-lebrand factor-containing organelles in heterolo-gous transfected CV-1 cells. EMBO J. 1993;12: 749-758.
10. Rondaij MG, Bierings R, KragtA, van Mourik JA, Voorberg J. Dynamics and plasticity of Weibel- Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol. 2006;26:1002-1007.
11. Haberichter SL, Jacobi P, Montgomery RR. Critical independent regions in the VWF propeptide and mature VWF that enable normal VWF storage. Blood. 2003;101:1384-1391.
12. Michaux G, Pullen TJ, Haberichter SL, Cutler DF. P-selectin binds to the D'-D3 domains of von Willebrand factor in Weibel-Palade bodies. Blood. 2006;107:3922-3924.
13. Bierings R, van den Biggelaar M, Kragt A, Mertens K, Voorberg J, van Mourik JA. Efficiency of von Willebrand factor-mediated targeting of IL-8 into Weibel-Palade bodies. J Thromb Hae-most. 2007;5:2512-2519.
14. Shahbazi S, Lenting PJ, Fribourg C, Terraube V, Denis CV, Christophe OD. Characterization of the interaction between von Willebrand factor and osteoprotegerin. J Thromb Haemost. 2007;5: 1956-1962.
15. Rosenberg JB, Greengard JS, Montgomery RR. Genetic induction of a releasable pool of factor VIII in human endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20:2689-2695.
16. Rosenberg JB, Foster PA, Kaufman RJ, et al. Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J Clin Invest. 1998;101:613-624.
17. Shi Q, Wilcox DA, Fahs SA, Kroner PA, Montgomery RR. Expression of human factor VIII under control of the platelet-specific alphaIIb promoter in megakaryocytic cell line as well as storage together with VWF. Mol Genet Metab. 2003; 79:25-33.
18. ilcox DA, Shi Q, Nurden P, et al. Induction of megakaryocytes to synthesize and store a releas-able pool of human factor VIII. J Thromb Hae-most. 2003;1:2477-2489.
19. van den Biggelaar M, Bierings R, Storm G, Voorberg J, Mertens K. Requirements for cellular co-trafficking of factor VIII and von Willebrand factor to Weibel-Palade bodies. J Thromb Hae-most. 2007;5:2235-2243.
20. Modderman PW, Beuling EA, Govers LA, et al. Determinants in the cytoplasmic domain of P-selectin required for sorting to secretory granules.Biochem J. 1998;336:153-161.
21. Jorieux S, Tuley EA, Gaucher C, Mazurier C, Sadler JE. The mutation Arg(53)→Trp causes von Willebrand disease Normandy by abolishing binding to factor VIII. Studies with recombinant von Willebrand factor. Blood. 1992;79:563-567.
22. Tuley EA, Gaucher C, Jorieux S, Worrall NK, Sadler JE, Mazurier C. Expression of von Wille-brand factor "Normandy": an autosomal mutation that mimics hemophilia A. Proc Natl Acad Sci U S A. 1991;88:6377-6381.
23. Raines G, Aumann H, Sykes S, StreetA. Multi-meric analysis of von Willebrand factor by mo-lecular sieving electrophoresis in sodium dodecyl sulphate agarose gel. Thromb Res. 1990;60:201-212.
24. Stel HV, Sakariassen KS, Scholte BJ, et al. Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium. Blood. 1984; 63:1408-1415.
25. Donath MJSH, Lenting PJ, van Mourik JA, Mertens K. The role of cleavage of the light chain at positions Arg1689 or Arg1721 in subunit interaction and activation of human blood coagulation factor VIII. J Biol Chem. 1995;270:3648-3655.
26. Leyte A, Mertens K, Distel B, et al. Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments. Bio- chem J. 1989;263:187-194.
27. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
28. Fribourg C, Meijer AB, Mertens K. The interface between the EGF2 domain and the protease domain in blood coagulation factor IX contributes to factor VIII binding and factor X activation. Biochemistry. 2006;45:10777-10785.
29. Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protoc. 2006; 1:241-245.
30. Romani de Wit T, Rondaij MG, Hordijk PL, Voorberg J, van Mourik JA. Real-time imaging of the dynamics and secretory behavior of Weibel-Palade bodies. Arterioscler Thromb Vasc Biol. 2003;23:755-761.
31. Kootstra NA, Matsumura R, Verma IM. Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Mol Ther. 2003;7:623-631.
32. Borchiellini A, Fijnvandraat K, ten Cate JW, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood. 1996; 88:2951-2958.
33. van Helden PMW, van den Berg HM, Gouw SC, et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol. 2008;142:644-652. 34. Michaux G, Hewlett LJ, Messenger SL, et al. Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Willebrand factor. Blood. 2003; 102:2452-2458.
34. Hilbert L, Nurden P, Caron C, et al. Type 2N von Willebrand disease due to compound heterozy- gosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propep- tide. Thromb Haemost. 2006;96:290-294.
35. van de Ven WJ, Voorberg J, Fontijn R, et al. Furin is a subtilisin-like proprotein processing enzyme in higher eukaryotes. Mol Biol Rep. 1990;14:265- 275.
36. de Mol NJ, Plomp E, Fischer MJ, Ruijtenbeek R. Kinetic analysis of the mass transport limited interaction between the tyrosine kinase lck SH2 domain and a phosphorylated peptide studied by a new cuvette-based surface plasmon resonance instrument. Anal Biochem. 2000;279:61-70.
37. Rich RL, Myszka DG. Survey of the year 2006 commercial optical biosensor literature. J Mol Recognit. 2007;20:300-366.
38. Kroner PA, Friedman KD, Fahs SA, Scott JP, Montgomery RR. Abnormal binding of factor VIII is linked with the substitution of glutamine for ar-ginine 91 in von Willebrand factor in a variant form of von Willebrand disease. J Biol Chem. 1991;266:19146-19149.
39. Cacheris PM, Nichols WC, Ginsburg D. Molecular characterization of a unique von Willebrand dis-ease variant: a novel mutation affecting von Wille-brand factor/factor VIII interaction. J Biol Chem. 1991;266:13499-13502.
40. Kroner PA, Foster PA, Fahs SA, MontgomeryRR. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor. Blood. 1996;87:1013-1021.
41. Hilbert L, Jorieux S, Proulle V, et al. Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-binding capacity. Br J Haematol. 2003;120:627-632.
42. Mazurier C, Gaucher C, Jorieux S, Goudemand M. Biological effect of desmopressin in eight patients with type 2N('Normandy') von Willebrand disease: Collaborative Group. Br J Haematol. 1994;88:849-854.
43. BlagoveshchenskayaAD, Hannah MJ, Allen S, Cutler DF. Selective and signal-dependent recruitment of membrane proteins to secretory granules formed by heterologously expressed von Willebrand factor. Mol Biol Cell. 2002;13: 1582-1593.
44. Harrison-Lavoie KJ, Michaux G, Hewlett L, et al. P-selectin and CD63 use different mechanisms for delivery to Weibel-Palade bodies. Traffic. 2006;7:647-662.
45. Journet AM, Saffaripour S, Cramer EM, Tenza D, Wagner DD. von Willebrand factor storage re-quires intact prosequence cleavage site. Eur J Cell Biol. 1993;60:31-41.
46. Michaux G, Abbitt KB, Collinson LM, Haberichter SL, Norman KE, Cutler DF. The physiological function of von Willebrand's factor depends on its tubular storage in endothelial Weibel-Palade bodies. Dev Cell. 2006;10:223-232.
47. Huang RH, Wang Y, Roth R, et al. Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor. Proc Natl Acad Sci U S A. 2008;105:482-487.
48. Babich V, Meli A, Knipe L, et al. Selective release of molecules from Weibel Palade bodies during a lingering kiss. Blood. 2008;11:5282-5290.
49. Bontempo FA, Lewis JH, Gorenc TJ, et al. Liver transplantation in hemophiliaA. Blood. 1987;69: 1721-1724.
50. Haberichter SL, Shi Q, Montgomery RR. Regulated release of VWF and FVIII and the biologic implications. Pediatr Blood Cancer. 2006;46:547-553.
51. Langenkamp E, Molema G. Microvascular endo-thelial cell heterogeneity: general concepts and pharmacological consequences for anti-angio-genic therapy of cancer. Cell Tissue Res. 2009; 335:205-222.
52. Federici AB, Mazurier C, Berntorp E, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease:results of a multicenter European study. Blood. 2004;103:2032-2038.